Test Discontinuation Memorandum

Effective September 3, 2014, the Medical Genetics Laboratories at Baylor College of Medicine will discontinue the following tests:

  • 9130 – Comprehensive Hereditary Cancer Panel (47 genes)
  • 9135 – Pheochromocytoma/Paraganglioma Panel (9 genes)
  • 9145 – High Risk Colorectal Panel (11 genes)
  • 9155 – High Risk Breast Cancer Panel (7 genes)
  • 9160 – Renal Cancer Panel (11 genes)
  • 9165 – Endocrine Cancer Panel (14 genes)
  • 9170 – Breast/Ovarian Cancer Panel (20 genes)
  • 9171 – Breast/Ovarian Cancer Panel – without BRCA1/2 (18 genes)
  • 9175 – Brain/CNS/PNS Cancer Panel (17 genes)
  • 9180 – GI/Colorectal Cancer Panel (18 genes)

In place of the tests above, we recommend the alternative options:

    • 20004 – Comprehensive Hereditary Cancer Panel (61 genes)
    • 22304 – Hereditary Brain/CNS/PNS Cancer Panel (17 genes)
    • 22404 – Hereditary Breast/Ovarian/Endometrial Cancer Panel (23 genes)
    • 22504 – Hereditary Renal Cancer Panel (12 genes)
    • 22604 – Hereditary Endocrine Cancer Panel (15 genes)
    • 22704 – Hereditary Leukemia/Lymphoma Panel (13 genes)
    • 22804 – Hereditary Colorectal/GI Panel (22 genes)
    • 22904 – Hereditary Melanoma Panel (4 genes)
    • 23004 – Hereditary High Risk Breast Cancer Panel (7 genes)
    • 23104 – Hereditary Pheochromocytoma/Paraganglioma Panel (9 genes)
    • 23204 – Hereditary High Risk Colorectal Cancer Panel (11 genes)
    • 23304 – Hereditary Pancreatic Cancer Panel (16 genes)
    • 23404 – Hereditary Prostate Cancer Panel (5 genes)
Previous Post
Test Discontinuation Memorandum
Next Post
Test Discontinuation Memorandum
Menu